GH Research PLC (NASDAQ:GHRS – Get Free Report) saw unusually-high trading volume on Thursday . Approximately 181,303 shares were traded during trading, a decline of 39% from the previous session’s volume of 296,380 shares.The stock last traded at $28.0950 and had previously closed at $27.75.
Analyst Ratings Changes
A number of research analysts have commented on GHRS shares. HC Wainwright restated a “buy” rating on shares of GH Research in a research note on Monday, August 10th. Guggenheim lifted their target price on shares of GH Research from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Cantor Fitzgerald boosted their target price on shares of GH Research from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Needham & Company LLC increased their price target on shares of GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of GH Research from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $45.00.
Check Out Our Latest Stock Report on GHRS
GH Research Price Performance
GH Research (NASDAQ:GHRS – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.06. As a group, equities analysts expect that GH Research PLC will post -1.2 EPS for the current year.
Institutional Trading of GH Research
A number of institutional investors have recently modified their holdings of GHRS. Squarepoint Ops LLC bought a new stake in shares of GH Research during the 2nd quarter valued at approximately $495,000. Braidwell LP acquired a new position in shares of GH Research during the second quarter worth $5,571,000. Royal Bank of Canada increased its holdings in shares of GH Research by 43.1% during the first quarter. Royal Bank of Canada now owns 2,590 shares of the company’s stock worth $36,000 after buying an additional 780 shares in the last quarter. Troluce Capital Advisors LLC lifted its stake in shares of GH Research by 165.4% in the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after acquiring an additional 617,260 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in GH Research during the 1st quarter worth $290,000. 56.90% of the stock is currently owned by institutional investors.
About GH Research
GH Research plc is a clinical-stage biopharmaceutical company headquartered in Dublin, Ireland. Founded in 2018, the company focuses on developing novel therapies for psychiatric and neurological disorders, with an emphasis on treatments that may offer rapid effects.
Its lead program, GH001, is an inhaled formulation of mebufotenin, also known as 5-MeO-DMT, being studied for treatment-resistant depression. GH Research is also developing additional formulations and delivery approaches based on mebufotenin, including the GH002 program.
Featured Articles
- Five stocks we like better than GH Research
- Apple Is Quietly Building an AI Advantage Few Expected
- How Serious Is the Regulatory Threat Now Facing Tesla’s Cybercab?
- Can ServisFirst Keep Delivering?
- CoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.
